Luteolin is a candidate compound for COPD treatment by regulating EGFR, MMP9, PTGS2, MMP2, APP, and ERBB2 through a preliminary decomposition experiment. This evidence concerns the gene PTGS2 and chronic obstructive pulmonary disease.